Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients Presented in part at the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 17–19, 2005, Orlando, Florida; and the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 24–26, 2006.
dc.contributor.author | Rosenberg, Jonathan E. | en_US |
dc.contributor.author | Weinberg, Vivian K. | en_US |
dc.contributor.author | Kelly, W. Kevin | en_US |
dc.contributor.author | Michaelson, Dror | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.contributor.author | Wilding, George | en_US |
dc.contributor.author | Gross, Mitchell | en_US |
dc.contributor.author | Hutcheon, Douglass | en_US |
dc.contributor.author | Small, Eric J. | en_US |
dc.date.accessioned | 2007-09-20T18:57:38Z | |
dc.date.available | 2008-09-08T14:25:12Z | en_US |
dc.date.issued | 2007-08-01 | en_US |
dc.identifier.citation | Rosenberg, Jonathan E.; Weinberg, Vivian K.; Kelly, W. Kevin; Michaelson, Dror; Hussain, Maha H.; Wilding, George; Gross, Mitchell; Hutcheon, Douglass; Small, Eric J. (2007)."Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients Presented in part at the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 17–19, 2005, Orlando, Florida; and the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 24–26, 2006. ." Cancer 110(3): 556-563. <http://hdl.handle.net/2027.42/56110> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/56110 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17577218&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC). METHODS. Patients with HRPC that progressed during or within 60 days of cessation of taxane chemotherapy were randomly selected with equal probability to ixabepilone 35 mg/m 2 intravenously every 3 weeks, or mitoxantrone 14 mg/m 2 intravenously every 3 weeks and prednisone 5 mg orally twice daily. Treatment continued until progression or toxicity; crossover was allowed. RESULTS. Forty-one patients were accrued to each arm of the study. The median number of cycles administered for each arm was 3. Median survival from protocol entry was 10.4 months with ixabepilone and 9.8 months with MP. Prostate-specific antigen (PSA) declines of ≥50% were observed in 17% of ixabepilone (95% CI, 7-32) and 20% of second-line MP patients (95% CI, 9-35). Partial responses were observed in 1 of 24 ixabepilone and in 2 of 21 MP patients with evaluable measurable disease. Median duration of second-line ixabepilone and MP treatment was 2.2 months and 2.3 months, respectively. For third-line crossover treatment, PSA declines of ≥50% were observed in 3 of 27 ixabepilone-treated and 4 of 15 MP-treated patients. Prior taxane response was associated with an increased likelihood of second-line ixabepilone or MP response. Low baseline lactate dehydrogenase and absence of visceral metastases independently predicted improved survival. The most common grade 3/4 toxicity associated with second-line treatment was neutropenia (54% of ixabepilone patients and 63% of MP patients). CONCLUSIONS. Ixabepilone and MP had modest activity as second-line chemotherapy for docetaxel-refractory HRPC. The median survival for the entire cohort treated in this study was 9.8 months. Cancer 2007. © 2007 American Cancer Society. | en_US |
dc.format.extent | 152583 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients Presented in part at the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 17–19, 2005, Orlando, Florida; and the American Society of Clinical Oncology Multidisciplinary Prostate Cancer Symposium, February 24–26, 2006. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California ; Fax: (415) 353-7779 ; J. E. Rosenberg has received research funding from Bristol-Myers Squibb. ; University of California at San Francisco, Division of Hematology/Oncology, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115 | en_US |
dc.contributor.affiliationother | University of San Francisco, Comprehensive Cancer Center Biostatistics Core, San Francisco, California | en_US |
dc.contributor.affiliationother | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York | en_US |
dc.contributor.affiliationother | Department of Medicine, Harvard Cancer Center, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin | en_US |
dc.contributor.affiliationother | Department of Medicine, Cedars-Sinai Comprehensive Cancer Institute, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California | en_US |
dc.contributor.affiliationother | Department of Medicine, University of California at San Francisco, Comprehensive Cancer Center, San Francisco, California | en_US |
dc.identifier.pmid | 17577218 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/56110/1/22811_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.22811 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.